Filter
Exclude
Time range
-
Near
Rare Diseases@CheckOrphan
May 19
Alterity Therapeutics Highlights Promising Phase 2 Multiple System Atrophy (MSA) Data and Advances ATH434 Toward Phase 3 Development - For More Information Visit shorturl.at/xjxUD @AlterityT #MSA #FDA #Multiple_System_Atrophy #Rare_Diseases #Orphan_Drugs
1
105
Rare Diseases@CheckOrphan
12 Aug 2025
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy - For More Information Visit shorturl.at/bufWC @TizianaLS #FDA #MSA #Rare_Diseases #Multiple_System_Atrophy #Rare_Diseases
1
4
162
NAN@NAN_Wiley
4 Oct 2022
(ORIGINAL ARTICLE) Pathological substrate of memory impairment in multiple system atrophy #MSA #multiple_system_atrophy doi.org/10.1111/nan.12844 @WileyNeuro

Neuropathology and Applied Neurobiology | BNS Journal | Wiley Online Library

α-Synuclein oligomers can be a possible pathological cause of memory impairment in multiple system atrophy (MSA).

onlinelibrary.wiley.com
2
4
Amber Sze@SzeAmber
10 Feb 2022
Identification of microRNAs for the early diagnosis of Parkinson’s disease and multiple system atrophy imrpress.com/journal/JIN/19/… #Parkinsons #microRNA #multiple_system_atrophy #neuroscience
Load more